Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00125-005-1707-5.pdf
Reference20 articles.
1. Mentlein R (2005) Therapeutic assessment of GLP-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential anti-diabetic drugs. Expert Opin Investig Drugs 14:57?64
2. Ahrén B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869?875
3. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874?2880
4. Brenner MB, Gromada L, Efanov AM, Bokvist K, Mest H-J (2003) Restoration of first-phase insulin secretion by the imidazoline compound LY374284 in pancreatic islets of diabetes db/db mice. Ann NY Acad Sci 1009:332?340
5. Ahrén B, Hughes TE (2004) Inhibition of DPP-4 augments insulin secretion in response to exogenously administered GLP-1, GIP, PACAP and GRP in mice. Endocrinology (in press)
Cited by 128 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Activatable Fluorescence and Bio/Chemiluminescence Probes for Aminopeptidases: From Design to Biomedical Applications;Advanced Materials;2024-09-05
2. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides;Current Protein & Peptide Science;2024-05
3. Identification of phytocompounds as potent inhibitors of sodium/glucose cotransporter-2 leading to diabetes treatment;Journal of Biomolecular Structure and Dynamics;2024-02-20
4. The Potential for Multi-Disease Treatment: Applications of Dipeptidyl Peptidase Inhibitors;Advances in Clinical Medicine;2024
5. Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial;Diabetes, Obesity and Metabolism;2023-09-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3